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In 2002, a debate took place in Catalonia as to whether we 
should change our research system. I participated in the Euro­
pean Parliamentary Technology Assessment (EPTA) confer­
ence held in Switzerland, where the Catalan branch was invited 
to become a member. At the time, we did not have a parlia­
mentary assessment commission. It was only then that we 
learned about its importance in advising members of Parlia­
ment on all research­related laws discussed on a regular basis. 
Thus, the Advisory Board of the Parliament of Catalonia for 
Science and Technology (CAPCIT), the Catalan branch of EPTA, 
was founded in 2008. CAPCIT is an example of the differences 
in the Catalan model for technology transfer. We strongly believe 
that we will only be able to emerge from the economic crisis in 
our country if we invest in a knowledge­based economy—one of 
the cornerstones of which is high­quality research. Of course, 
this is not the only criterion, but it is an absolutely necessary one. 
That is why, about 15 years ago, we implemented a new re­
search policy in Catalonia. Its three basic guidelines are as fol­
lows: First of all, strong instruments must be put in place to at­
tract and retain both talent and an open system of research. The 
best example of this is the Catalan Institution for Research and 
Advanced Studies (ICREA), created in response to the need to 
seek new hiring formulas competitive with those of other re­
search systems and to recruit to the Catalan R&D system top 
scientists capable of leading new research groups, strengthen­
ing existing ones and establishing new lines of research. Sec­
ond, the country profits from a large­scale infrastructure for or­
ganizing science, consisting of a system of public, autonomous 
research centres. Third, this large­scale system must be at the 
disposal of our research community. 
We think that the results over the past 15 years have been 
very good for a small country, such as ours: Catalonia con­
tributes 1.5 % of the population of Europe and produces 3 % 
of Europe’s total scientific production. We also attract 2 % of 
the 7th Framework Programme funds, and in terms of ERC 
grants per million inhabitants, Catalonia is third in the Euro­
pean Union (if Israel and Switzerland are included in an ex­
panded list, Catalonia is 5th in the ranking). But having at­
tained a high level of research, the Catalan system faces the 
enormous challenge of converting this knowledge to eco­
nomic gain. In this debate, of course, the Government plays a 
role, but so does Parliament. Thus, working with CAPCIT, the 
Parliament needs to define the path to be taken by Catalonian 
research in a knowledge­based economy.
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Genomic technologies have the potential to transform the 
delivery of healthcare in Europe: (i) by providing vital insights 
that support the more accurate diagnosis of diseases and (ii) by 
informing therapeutic decisions, so that more patients receive 
the right treatment at the right time [1]. These two aims go 
hand in hand with preventive care, by extending our under­
standing of the risk of disease and helping us to quickly control 
new outbreaks of infectious diseases. 
Preventive care is implicitly linked to prognosis and predic­
tion. But, as a matter of fact, the challenge of improving out­
comes through prognostic and predictive information is not 
new one in medicine. Indeed, it can be traced back to, at least, 
Hippocratic times. What has changed in the last few years, 
however, is the strength of our expectations from this accumu­
lated information. Until recently, it was assumed that we could 
identify prognostic factors for ‘subgroups’ of patients that 
would explain their different prognoses, while also recognizing 
common characteristics. Today, our expectations have been 
raised, and accurate prognostic judgments are expected on an 
‘individual patient’ basis [2]. 
Personalized medicine is the term used to herald this incipi­
ent prognostic transformation of biomedicine. It refers to 
healthcare guided by detailed prognostic and predictive infor­
mation that is formulated for each patient. Nonetheless, some 
scientists would argue that the era of personalized medicine 
has not yet arrived; instead we are only in an era of stratified 
medicine, because mainly what we are able to predict is the 
risk for a patient subgroup. 
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Of greater concern is that the benefits of biomedical sci­
ence and clinical and public health research have not been 
made available to everyone. Personalized or stratified, if you 
will, medicine will essentially allow those in rich countries to 
create individually tailored drug regimens and behavioural 
modifications for overcoming predicted individual diseases 
risks, thus creating a new field of ‘boutique medicine,’ as Bar­
ry Bloom wrote in Nature more than a decade ago [3]. Yet, 
much of the knowledge derived from biomedical science and 
the resources to obtain boutique treatment and prevention to 
overcome these risks will simply not be available to 85 % of 
the world’s population, i.e. the developing world. The benefits 
conferred by personalized medicine, together with considera­
tions regarding sustainability, bioethics, social responsibili­
ties, and the challenges or limits to forecasting in personal­
ized medicine were the topics discussed at the 2012 Annual 
EPTA Meeting in Barcelona, “From Genes to Jeans: Chal­
lenges on the Road to Personalised Medicine.” 
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